Daniel Abravanel

Daniel Abravanel, MD, PhD, is a physician-scientist and Instructor in Medicine at Harvard Medical School, with primary affiliations at Dana-Farber Cancer Institute, the Broad Institute of Harvard and MIT, and Brigham and Women's Hospital. He specializes in medical oncology with a clinical focus on breast cancer, including early and advanced stages, and is deeply engaged in translational and basic research on therapeutic response and resistance mechanisms.

• Harvard Medical School – Instructor in Medicine
• Dana-Farber Cancer Institute – Research and Clinical Care
• Broad Institute of Harvard and MIT – Collaborative Research
• Brigham and Women's Hospital – Internal Medicine Residency Training

Dr. Abravanel received his PhD in Cell and Molecular Biology and MD from the University of Pennsylvania, completing his residency at Brigham and Women's Hospital and fellowship in Medical Oncology at the Dana-Farber/Mass General Brigham program, where he served as chief fellow. His research interests lie at the intersection of molecular oncology and precision medicine, aiming to improve treatment outcomes in breast cancer through mechanistic understanding of drug resistance.

His work spans both laboratory-based discovery and clinical application, reflecting a strong commitment to bridging science and patient care. Though no publications are listed in the provided text, his affiliation with leading institutions suggests active contributions to cancer research. He is board certified in Internal Medicine (2019) and Medical Oncology (2021).

Dr. Abravanel has received high patient satisfaction ratings, with verified patients praising his knowledge, clarity, empathy, and responsiveness. He is recognized for his ability to communicate complex medical information clearly and compassionately, making him a trusted clinician in oncology care.

While no formal advising or grant activity is detailed, his role as a physician-scientist implies involvement in research mentorship and potential grant-funded projects. He is likely part of larger collaborative teams at Dana-Farber and the Broad Institute focused on cancer genomics and therapeutic development.

Dr. Abravanel practices at the Dana-Farber Cancer Institute in Boston, MA, where he contributes to the Breast Oncology program, integrating cutting-edge research into clinical practice to advance personalized cancer therapy.